The preterm birth prevention and management market is estimated at USD 2.1 billion in 2026 and is forecast to register a 10.2% CAGR between 2026 and 2036. In 2026, progesterone therapy holds 61.5% of therapy type sales and parenteral administration represents 79.0% within the route of administration segment.